Journal of the National Cancer Center最新文献

{"title":"The unique genomic landscape and prognostic mutational signature of Chinese clear cell renal cell carcinoma","authors":"Wenhao Xu ,&nbsp;Aihetaimujiang Anwaier ,&nbsp;Wangrui Liu ,&nbsp;Xi Tian ,&nbsp;Jiaqi Su ,&nbsp;Guohai Shi ,&nbsp;Yuanyuan Qu ,&nbsp;Hailiang Zhang ,&nbsp;Dingwei Ye","doi":"10.1016/j.jncc.2022.07.001","DOIUrl":"10.1016/j.jncc.2022.07.001","url":null,"abstract":"<div><h3>Background</h3><p>The genomic background affects the occurrence and metastasis of cancers, including clear cell renal cell carcinoma (ccRCC). However, reports focusing on the prognostic mutational signature of Chinese ccRCC are lacking.</p></div><div><h3>Methods</h3><p>Overall, 929 patients, including a training cohort with Chinese patients (<em>n</em> = 201), a testing cohort with Caucasian patients (<em>n</em> = 274), and a validation cohort (<em>n</em> = 454) were analyzed for the genomic landscape of ccRCC. Then, machine-learning algorithms were used to identify and evaluate the genomic mutational signature (GMS) in ccRCC. Analyses for prognosis, immune microenvironment, association with independent clinicopathological features, and predictive responses for immune checkpoint therapies (ICTs) were performed.</p></div><div><h3>Results</h3><p>The DNA variation data of 929 patients with ccRCC suggested markedly differential genomic mutational frequency of the most frequent genes, such as <em>VHL, PBRM1, BAP1, SETD2</em>, and <em>KDM5C</em> between the Chinese and Caucasian populations. <em>PBRM1</em> showed significant co-occurrence with <em>VHL</em> and <em>SETD2</em>. We then successfully identified a seven-gene mutational signature (GMS^Mut) that included mutations in <em>FBN1, SHPRH, CELSR1, COL6A6, DST, ABCA13</em>, and <em>BAP1</em>. The GMS^Mut significantly predicted progressive progression (<em>P</em> &lt; 0.0001, HR = 2.81) and poor prognosis (<em>P</em> &lt; 0.0001, HR = 3.89) in the Chinese training cohort. Moreover, ccRCC patients with the GMS^Mut had poor survival rates in the testing cohort (<em>P</em> = 0.020) and poor outcomes were predicted for those treated with ICTs in the validation cohort (<em>P</em> = 0.036). Interestingly, a favorable clinical response to ICTs, elevated expression of immune checkpoints, and increased abundance of tumor-infiltrated lymphocytes, specifically CD8⁺ T cells, Tregs, and macrophages, were observed in the GMS^Mut cluster.</p></div><div><h3>Conclusions</h3><p>This study described the pro-tumorigenic GMS^Mut cluster that improved the prognostic accuracy in Chinese patients with ccRCC. Our discovery of the novel independent prognostic signature highlights the relationship between tumor phenotype and genomic mutational characteristics of ccRCC.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"2 3","pages":"Pages 162-170"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005422000394/pdfft?md5=2c76c74609e1633cca97c439c2d26e47&pid=1-s2.0-S2667005422000394-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46820470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Head-to-head comparison of 7 high-sensitive human papillomavirus nucleic acid detection technologies with the SPF10 LiPA-25 system","authors":"Jian Yin ,&nbsp;Shuqian Cheng ,&nbsp;Daokuan Liu ,&nbsp;Yabin Tian ,&nbsp;Fangfang Hu ,&nbsp;Zhigao Zhang ,&nbsp;Tiancen Zhu ,&nbsp;Zheng Su ,&nbsp;Yujing Liu ,&nbsp;Sumeng Wang ,&nbsp;Yiwei Liu ,&nbsp;Siying Peng ,&nbsp;Linlin Li ,&nbsp;Sihong Xu ,&nbsp;Chuntao Zhang ,&nbsp;Youlin Qiao ,&nbsp;Wen Chen","doi":"10.1016/j.jncc.2022.06.003","DOIUrl":"https://doi.org/10.1016/j.jncc.2022.06.003","url":null,"abstract":"<div><h3>Background</h3><p>The SPF10 LiPA-25 system for human papillomavirus (HPV) detection with high analytical performance is widely used in HPV vaccine clinical trials. To develop and evaluate more valent HPV vaccines, other comparable methods with simpler operations are needed.</p></div><div><h3>Methods</h3><p>The performance of the LiPA-25 against that of other 7 assays, including 4 systems based on reverse hybridization (Bohui-24, Yaneng-23, Tellgen-27, and Hybribio-16) and 3 real-time polymerase chain reaction (PCR) assays (Hybribio-23, Bioperfectus-21, and Sansure-26), was evaluated in selected 1726 cervical swab and 56 biopsy samples. A total of 15 HPV genotypes (HPV 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 66) were considered for comparison for each HPV type.</p></div><div><h3>Results</h3><p>Among the swab samples, compared to LiPA-25, compatible genotypes were observed in 94.1% of samples for Hybribio-23, 92.8% for Yaneng-23, 92.6% for Bioperfectus-21, 92.4% for Hybribio-16, 91.3% for Sansure-26, 89.7% for Bohui-24, and 88.0% for Tellgen-27. The highest overall agreement of the 15 HPV genotypes combined was noted for Hybribio-23 (<em>κ</em> = 0.879, McNemar's test: <em>P</em> = 0.136), followed closely by Hybribio-16 (<em>κ</em> = 0.877, <em>P</em>&lt; 0.001), Yaneng-23 (<em>κ</em> = 0.871, <em>P</em> &lt; 0.001), Bioperfectus-21 (<em>κ</em> = 0.848, <em>P</em> &lt; 0.001), Bohui-24 (<em>κ</em> = 0.847, <em>P</em> &lt; 0.001), Tellgen-27 (<em>κ</em> = 0.831, <em>P</em> &lt; 0.001), and Sansure-26 (<em>κ</em> = 0.826, <em>P</em> &lt; 0.001). Additionally, these systems were also highly consistent with LiPA-25 for biopsy specimens (all, <em>κ</em> &gt; 0.897).</p></div><div><h3>Conclusions</h3><p>The levels of agreement for the detection of 15 HPV types between other 7 assays and LiPA-25 were all good, and Hybribio-23 was most comparable to LiPA-25. The testing operation of HPV genotyping should also be considered for vaccine and epidemiological studies.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"2 3","pages":"Pages 148-154"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005422000382/pdfft?md5=e80ae9bd8e374590495df7aa00b5c6f8&pid=1-s2.0-S2667005422000382-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91761847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The evolving role of radiation therapy as treatment for liver metastases","authors":"Khalid Alrabiah ,&nbsp;Guixiang Liao ,&nbsp;Qi Shen ,&nbsp;Chi-Leung Chiang ,&nbsp;Laura A. Dawson","doi":"10.1016/j.jncc.2022.06.004","DOIUrl":"10.1016/j.jncc.2022.06.004","url":null,"abstract":"<div><p>Liver metastases occur commonly in many solid malignancies. With advances in systemic therapies and increased life expectancy, the role of using local therapies in oligo-metastases is rapidly increasing. Stereotactic body radiotherapy (SBRT) is an emerging precision therapy that is being used more frequently in the treatment for unresectable liver metastases. This review focuses on the role of SBRT for liver metastases, principles of treatment, clinical outcomes, toxicity, and optimal patient selection.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"2 3","pages":"Pages 183-187"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005422000400/pdfft?md5=55c4ca7a71dc99cd73b51e79533e8c5a&pid=1-s2.0-S2667005422000400-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48264219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of interval between surgery and postoperative radiotherapy in major salivary gland carcinoma","authors":"Wenbin Yan ,&nbsp;Xiaomin Ou ,&nbsp;Chunying Shen ,&nbsp;Chaosu Hu","doi":"10.1016/j.jncc.2022.06.001","DOIUrl":"10.1016/j.jncc.2022.06.001","url":null,"abstract":"<div><h3>Background</h3><p>Radiotherapy following primary operation is strongly recommended for salivary gland carcinomas (SGCs) with adverse features. The interval between surgery and the initiation of radiotherapy (SRT) varied and a prolonged SRT may cause failure of cancer treatment. However, the association of SRT with survival is unclear in major SGCs.</p></div><div><h3>Methods</h3><p>This retrospective study included a total of 346 patients who underwent radiotherapy after the primary operation from Fudan University Shanghai Cancer Center from 2005 to 2020. The best cutoff value of the SRT was determined by the maximum log-rank statistic method. The primary endpoint of the study was overall survival (OS). Correlations between variables and OS were conducted by the univariable analysis using the Log-rank method, and a multivariate Cox proportional hazards regression was performed to identify the independent prognostic factors associated with OS. The estimated survival rates were captured using the Kaplan-Meier method.</p></div><div><h3>Results</h3><p>With a median follow-up time of 70.31 months, the estimated 5-year OS, LRFS, and DMFS were 83.3%, 80.1%, and 75.9%, respectively. The cutoff value for SRT was 8.5 weeks, while age, T stage, N stage, perineural invasion (PNI), pathological aggression, chemotherapy, and SRT were associated with OS in the univariable analysis. The Cox regression analysis demonstrated that older age (<em>P</em> &lt; 0.001), T3-4 tumors (<em>P</em> = 0.007), positive N stage (<em>P</em> &lt; 0.001), pathological aggression (<em>P</em> = 0.014), and longer SRT (<em>P</em> = 0.009) were independent prognostic factors for major SGCs. Using the stratification model, we observed that delay in the SRT was associated with worse OS (<em>P</em> = 0.006) in the high-risk group, whereas no significant difference was observed in the low-risk subgroup (<em>P</em> = 0.61).</p></div><div><h3>Conclusions</h3><p>The delay in the initiation of postoperative radiotherapy may be a prognostic factor for patients with major SGCs. It was suggested that radiotherapy should be delivered within 8.5 weeks following the operation, especially for patients with ≥2 risk factors, including older age, high pathological aggression, T3-4 tumors, and positive N stage.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"2 3","pages":"Pages 188-194"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005422000345/pdfft?md5=01e68d9e21ec1eaeea286ee7947f1605&pid=1-s2.0-S2667005422000345-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41757280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung cancer incidence and mortality in China: Updated statistics and an overview of temporal trends from 2000 to 2016","authors":"Rongshou Zheng ,&nbsp;Siwei Zhang ,&nbsp;Shaoming Wang ,&nbsp;Ru Chen ,&nbsp;Kexin Sun ,&nbsp;Hongmei Zeng ,&nbsp;Li Li ,&nbsp;Wenqiang Wei ,&nbsp;Jie He","doi":"10.1016/j.jncc.2022.07.004","DOIUrl":"10.1016/j.jncc.2022.07.004","url":null,"abstract":"<div><h3>Background</h3><p>Updated systematic statistics on lung cancer are the underpinning cornerstones for formulating prevention and control strategies for the disease. The incidence and mortality data of lung cancer in China in 2016 were estimated, and also used to analyze the temporal trends of lung cancer from 2000 up to 2016 in this study.</p></div><div><h3>Methods</h3><p>The burden of lung cancer in China in 2016 was estimated using data from 487 cancer registries, which were abstracted from the database of the National Cancer Center of China (NCC). The temporal trends were estimated with the data of 2000 to 2016 from 22 cancer registries.</p></div><div><h3>Results</h3><p>About 828,100 new lung cancer cases and 657,000 lung cancer deaths were estimated in China in 2016. The crude incidence and mortality rates in the eastern region were the highest nationwide. The incidence and mortality of lung cancer increased with age, and most of the new cases occurred in the age group of over 60 years. The age-standardized incidence increased by about 0.8% per year during 2000 to 2016, especially in woman, whose annual increase rate reached 2.1%. The age-standardized mortality rate decreased by about 0.6% per year, with a decrease of 1.3% per year in urban areas and an increase of 2.3% per year in rural areas. The numbers of new cases and deaths increased by 162.6% and 123.6%, respectively, during 2000 to 2016, which can be explained mainly by the change of the age structure.</p></div><div><h3>Conclusions</h3><p>The burden of lung cancer is serious in China, and increased especially rapidly for women in rural areas. The disease is expected to threaten the lives of more people in the future due to factors such as aging and population growth. Lung cancer prevention and control strategies and resources should be leveraged toward women and rural areas in the future.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"2 3","pages":"Pages 139-147"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005422000436/pdfft?md5=47a5d1d198110bf4ca0f5ab2ceaa3198&pid=1-s2.0-S2667005422000436-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47536596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival of patients with gastric cancer surgically treated at the National Cancer Center of China from 2011 to 2018 according to stage at diagnosis","authors":"Wenzhe Kang ,&nbsp;Hongmei Zeng ,&nbsp;Jianping Xiong ,&nbsp;Yang Li ,&nbsp;Peng Jin ,&nbsp;Xinxin Shao ,&nbsp;Haitao Hu ,&nbsp;Bingzhi Wang ,&nbsp;Yibin Xie ,&nbsp;Yantao Tian","doi":"10.1016/j.jncc.2022.07.002","DOIUrl":"10.1016/j.jncc.2022.07.002","url":null,"abstract":"<div><h3>Objective</h3><p>The postoperative survival rates of patients with gastric cancer at different stages treated at the National Cancer Center (NCC) of China have not been reported. Therefore, we evaluated the survival of patients with gastric cancer who underwent surgery at the NCC from 2011 to 2018 to provide baseline information for further studies.</p></div><div><h3>Methods</h3><p>We identified 7,301 patients with primary gastric carcinoma who underwent surgery at the NCC between January 2011 and May 2018; among these, 5,008 patients were enrolled in this study. Follow up was completed on April 30, 2020. We analyzed the 5-year survival according to the stage, sex, age, and other clinicopathological features.</p></div><div><h3>Results</h3><p>Five-year survival rates of patients with pTNM stages IA, IB, IIA, IIB, IIIA, IIIB, IIIC, and IV treated at the NCC were 94.9%, 91.8%, 86.5%, 76.1%, 61.1%, 44.2%, 29.7%, and 8.1%, respectively, which were similar to those reported in Japan during the same period. Five-year survival rates of patients with ypTNM stages I, II, III, and IV were 93.1%, 63.2%, 27.2%, and 0.0%, respectively. In multivariable analysis, age, signet ring cell carcinoma, adjuvant chemotherapy, and degree of differentiation were revealed as important prognostic factors.</p></div><div><h3>Conclusion</h3><p>The survival rates of patients with gastric cancer treated at the NCC have been significantly improved, reaching the levels of Japan in the same period.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"2 3","pages":"Pages 132-138"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005422000412/pdfft?md5=1f2a1b83bdbb50a400f52e227268dc3b&pid=1-s2.0-S2667005422000412-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49415324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Head-to-head comparison of 7 high-sensitive human papillomavirus nucleic acid detection technologies with SPF10 LiPA-25 system","authors":"J. Yin, S. Cheng, Daokuan Liu, Yabin Tian, Fangfang Hu, Zhigao Zhang, Tiancen Zhu, Zheng Su, Yujing Liu, Sumeng Wang, Yiwei Liu, Siying Peng, Linlin Li, Sihong Xu, Chun-tao Zhang, Youlin Qiao, Wen Chen","doi":"10.1016/j.jncc.2022.06.003","DOIUrl":"https://doi.org/10.1016/j.jncc.2022.06.003","url":null,"abstract":"","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43005475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and mortality of cervical cancer in China in 2015","authors":"Xiuying Gu ,&nbsp;Gang Sun ,&nbsp;Rongshou Zheng ,&nbsp;Siwei Zhang ,&nbsp;Hongmei Zeng ,&nbsp;Kexin Sun ,&nbsp;Shaoming Wang ,&nbsp;Ru Chen ,&nbsp;Wenqiang Wei ,&nbsp;Jie He","doi":"10.1016/j.jncc.2022.01.002","DOIUrl":"10.1016/j.jncc.2022.01.002","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;p&gt;To estimate the incidence and mortality of cervical cancer in China based on the cancer registration data in 2015, collected by the National Central Cancer Registry (NCCR).&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;p&gt;There were 501 cancer registries that submitted data to the NCCR, whose data were the basis for estimating the incidence and mortality of cervical cancer in China in 2015. After evaluating the data quality, 368 registries’ data were accepted for the analysis and stratified by area (urban/rural) and age group. Combined with data on the national population in 2015, the nationwide incidence and mortality of cervical cancer were estimated. Cervical Cancer cases of 22 cancer registries were applied for temporal trends from 2000 to 2015. The Chinese population census in 2000 and Segi's population were used to calculate age-standardized incidence and mortality rates.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;An estimated 111,000 new cases were attributed to cervical cancer in China in 2015, accounting for 6.24% of all female new cancer cases in that year in China. The crude rate (CR) of incidence and age-standardized incidence rates by the China standard population (ASIRC) and by Segi's world standard population (ASIRW) of cervical cancer were 16.56/100,000, 11.78/100,000, and 10.86/100,000, respectively. The cumulative incidence rate from birth to 74 years old was 1.15%, whereas the calculation of incidence rates over the truncated age range of 35-64 years by Segi's world standard population (T-ASIRW) was 27.66/100,000. The estimates of cervical cancer deaths were about 33,800 and 3.94% of all female cancer-related deaths in China in 2015, with a crude mortality rate of 5.04/100,000. The age-standardized mortality rates adjusted by the Chinese standard population (ASMRC) and by world Segi's population (ASMRW) were 3.29/100,000 and 3.15/100,000, respectively, with a cumulative mortality rate (0-74 years old) of 0.35%. Both the incidence and mortality were higher in rural than in urban areas. The age-specific cervical cancer incidence significantly increased with age, particularly after age 25 years, and peaked at 50–54 years old, whereas age-specific mortality increased rapidly after 35 years old, peaking at 80–84 years old. The age-standardized incidence rates increased by about 8.6 (95% CI: 6.9, 10.3) per year during the period of 2000−2015. The age at diagnosis of patients with cervical cancer tended to be younger. In rural areas, the mean age at diagnosis decreased about 3.22 years from 2000 to 2015 (&lt;em&gt;β&lt;/em&gt; = –0.33, &lt;em&gt;P&lt;/em&gt; &lt; 0.001).&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;p&gt;China has a high burden of cervical cancer and important disparities among different regions. Especially in the middle and western areas and rural areas, cervical cancer is a serious issue in women's health, and prevention strategies need to be enhanced. Prevention and control strategies need to be enhanced and implemented with reference to local status, ","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"2 2","pages":"Pages 70-77"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005422000023/pdfft?md5=b0c06a7ff86290d10e1fa51c88f7e7ea&pid=1-s2.0-S2667005422000023-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45542135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy for small cell lung cancer in current clinical practice guidelines","authors":"Haiyan Zeng ,&nbsp;Dirk K.M. De Ruysscher ,&nbsp;Xiao Hu ,&nbsp;Danyang Zheng ,&nbsp;Li Yang ,&nbsp;Umberto Ricardi ,&nbsp;Feng-Ming Spring Kong ,&nbsp;Lizza E.L. Hendriks","doi":"10.1016/j.jncc.2022.02.003","DOIUrl":"10.1016/j.jncc.2022.02.003","url":null,"abstract":"<div><p>Several guidelines including radiotherapy recommendations exist worldwide for the treatment of small cell lung cancer (SCLC). To evaluate the differences in radiotherapy recommendations we conducted a systematic review. PubMed and the sites of medical societies were searched for SCLC guidelines published in either English, Chinese, or Dutch. This was limited to January 2018 till February 2021 to only include up-to-date recommendations. Data was extracted and compared regarding the guideline's development method and radiotherapy recommendations. Eleven guidelines were identified (PubMed n=4, societies n=7) from Spain (n=1), Canada (n=1), America (n=3), United Kingdom (n=1), the Netherlands (n=1), and China (n=3), respectively. Nine guidelines assessed the strength of evidence (SOE) and specified the strength of recommendation (SOR), although methods were different. The major radiotherapy recommendations are similar although differences exist in thoracic radiotherapy (TRT) dose, time, and volume. Controversial areas are TRT in resected stage I-IIA (pN1), prophylactic cranial irradiation (PCI) in resected as well as unresected stage I-IIA, stereotactic body radiation therapy (SBRT) in unresected stage I-IIA, PCI time, and PCI versus magnetic resonance imaging (MRI) surveillance in stage IV. The existence of several overlapping guidelines for SCLC treatment indicates that guideline development is (unnecessarily) repeated by different organizations or societies. Improvement could be made by better international collaboration to avoid duplicating unnecessary work, which would spare a lot of time and resources. Efforts should be made to work together on controversial or unknown fields.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"2 2","pages":"Pages 113-125"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005422000059/pdfft?md5=f3ee2faf3d13f2558c706c7f51de5a93&pid=1-s2.0-S2667005422000059-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42246112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting MEN1-deficient tumors with DHODH inhibitor","authors":"Lei Zheng","doi":"10.1016/j.jncc.2022.03.001","DOIUrl":"10.1016/j.jncc.2022.03.001","url":null,"abstract":"","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"2 2","pages":"Page 69"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005422000163/pdfft?md5=ad98ef46d3c40c3cc2e745289cceabc7&pid=1-s2.0-S2667005422000163-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47693410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}